Education
About Us
Working with TipRanks
Follow Us
Amylyx Pharmaceuticals, Inc. (AMLX)
:AMLX
Earnings Data
Report Date
Apr 01, 2026After Close (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
-0.35Last Year’s EPS
-0.42Same Quarter Last Year
Strong Buy
Based on 10 Analysts Ratings
Earnings Call Summary
Q3 2025
Earnings Call Date:Nov 06, 2025|
% Change Since:
|
Earnings Call Sentiment|Positive
The earnings call reflects a generally positive sentiment with strong financial performance and progress across multiple programs. However, there is a noted delay in the LUCIDITY trial enrollment, indicating some operational challenges. The urgency and unmet need in the PBH market further underscore the importance of avexitide's development.Company Guidance
Strong Financial Position
Amylyx Pharmaceuticals ended the third quarter with a cash position of $344 million, up from $181 million at the end of the second quarter, due to the completion of a public offering in September which provided approximately $191 million of net proceeds.
Advancement in ALS Program
The company fully enrolled Cohort 1 in the Phase I LUMINA trial for AMX0114 and plans to share safety data at an upcoming ALS and MMD symposium. Biomarker data is anticipated to be available in the coming months.
Decrease in Operating Expenses
Total operating expenses for the quarter were $36 million, down 53% from the same period in 2024, primarily due to decreased onetime expenses related to the acquisition of avexitide.
FDA Breakthrough Therapy Designation for Avexitide
Avexitide, the company's investigational inhibitor of GLP-1 receptor activity, continues to progress with high participant interest in the LUCIDITY trial, and has FDA breakthrough therapy designation.
AMLX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
AMLX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 06, 2025 | $13.24 | $12.46 | -5.89% |
Aug 07, 2025 | $8.19 | $7.84 | -4.27% |
May 08, 2025 | $4.87 | $4.58 | -5.95% |
Mar 04, 2025 | $3.00 | $3.01 | +0.33% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Amylyx Pharmaceuticals, Inc. (AMLX) report earnings?
Amylyx Pharmaceuticals, Inc. (AMLX) is schdueled to report earning on Apr 01, 2026, After Close (Confirmed).
What is Amylyx Pharmaceuticals, Inc. (AMLX) earnings time?
Amylyx Pharmaceuticals, Inc. (AMLX) earnings time is at Apr 01, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is AMLX EPS forecast?
AMLX EPS forecast for the fiscal quarter 2025 (Q4) is -0.35.
